Back to results
US 6,866,837 B2Granted
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
AssigneeMallinckrodt Inc.
InventorsJean-Claude Reubi, Wout A. Breeman, Ananthachari Srinivasan
Life of this patent
Estimating the term…
Abstract
Compounds and methods for the diagnosis and treatment of tumors, including breast and prostate tumors and metastases thereof using radiolabelled peptides that bind to GRP receptors. The peptides are Bombesin analogs wherein the first and optionally the third amino acid are modified.
Claims15
A pharmaceutical composition for targeting a selected biological site, the composition comprising:
- a peptide AA1-Gln-AA3-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
- wherein AA1 is a cyclic amino acid of the formula
- wherein n=0 to 5;
- wherein AA3 is selected from the group consisting of Arg,
- wherein n′=0 to 2, and
- wherein n=1 to 3 and n′=0 to 3.
3 more elements
A kit for the diagnosis of breast or prostate tumors or metastases of such tumors in a human comprising:
- (a) a peptide AA1-Gln-AA3-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
- wherein AA1 is a cyclic amino acid of the formula
- wherein n=0 to 5;
- wherein AA3 is selected from the group consisting of Arg,
- wherein n′=0 to 2, and
- wherein n=1 to 3 and n′=0 to 3;
- (b) a radioisotope;
- and
- (c) adjuvants suitable for administering the resultant combination to human.
6 more elements
A kit for the treatment of breast or prostate tumors or metastases of such tumors in a human comprising:
- (a) a peptide AA1-Gln-AA3-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
- wherein AA1 is a cyclic amino acid of the formula
- wherein n=0 to 5;
- wherein AA3 is selected from the group consisting of Arg,
- wherein n′=0 to 2, and
- wherein n=1 to 3 and n′=0 to 3;
- (b) a radioisotope:
- and
- (c) adjuvants suitable for binding the radioisotope to the peptide and administering the resultant combination to a human.
6 more elements
Dependencies are inferred from the claim text.